Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 911K | 4M | 2M | 2M | 2M |
| Gross Profit | -1M | 3M | -4M | 396K | 541K |
| Operating Income | -2M | -3M | -6M | -5M | -6M |
| EBITDA | 18K | 2M | -5M | -5M | -2M |
| Net Income | -417K | -583K | -8M | -11M | -6M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.035
+0.00% today
Window Change
+0.00%
Window
May 29, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars · May 29, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Panacea Life Sciences Holdings, Inc. (PLSH) is a Healthcare stock with listed on OTC. The stock last traded around $0.04 and up 0.0% across the available one-year price window (May 29, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of -77.8%, EPS growth of +77.8%, a dividend yield of 0.0%. What stands out right now is revenue -77.8%, EPS +77.8%, free cash flow -10.4% with operating margin -192.6% and ROIC -31.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PLSH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PLSH
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PLSH Max Drawdown
-8.57%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PLSH and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$2.1M
+26.6% YoY
FY Net Income
-$6.1M
+44.8% YoY
Free Cash Flow
-$4.1M
-54.5% YoY
Revenue Growth
-77.8%
EPS Growth
+77.8%
Gross Margin
-133.9%
Net Margin
-45.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 911K | 4M | 2M | 2M | 2M |
| Gross Profit | -1M | 3M | -4M | 396K | 541K |
| Operating Income | -2M | -3M | -6M | -5M | -6M |
| EBITDA | 18K | 2M | -5M | -5M | -2M |
| Net Income | -417K | -583K | -8M | -11M | -6M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 41K | 1M | 101K | 7K | 20K |
| Total Assets | 6M | 11M | 18M | 19M | 24M |
| Total Liabilities | 215K | 19M | 26M | 22M | 17M |
| Shareholder Equity | 5M | -8M | -8M | -2M | 7M |
| Total Debt | 215K | 15M | 19M | 19M | 15M |
| Net Debt | 173K | 13M | 19M | 19M | 15M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
4M
-63.4% YoY
Capital Expenditures
163K
+33.2% YoY
Free Cash Flow
4M
-54.5% YoY
Key ratios
Gross Margin
-133.9%
Operating Margin
-192.6%
Net Margin
-45.8%
ROE
14.7%
Debt / Equity
0.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.